The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Secondary safety analysis of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in DESTINY-Breast05: Clinical and demographic risk factors of interstitial lung disease (ILD) and radiation pneumonitis (RP).
 
Michael Untch
Honoraria - AstraZeneca; AstraZeneca (Inst); Baxter Middle East; Daiji Sankyo (Inst); Eisai Germany (Inst); Lilly (Inst); Menarini Group (Inst); MSD Oncology (Inst); Myriad Genetics (Inst); Novartis (Inst); Roche Pharma AG (Inst); Sanofi (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); BeOne Germany (Inst); CD Pharma (Inst); ClinSol; Daiichi Sankyo Europe GmbH (Inst); EuroBio Scientific (Inst); Lilly (Inst); Menarini Group (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche Pharma AG (Inst); Sandoz Hexal (Inst); Sanofi Aventis GmbH (Inst)
 
Zhimin Shao
No Relationships to Disclose
 
Chiun-Sheng Huang
Honoraria - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiich Sankyo; EirGenix; Gilead Sciences; Lilly; Novartis; Pfizer; Roche
Speakers' Bureau - Daiich Sankyo; Lilly; MSD; Novartis; Roche
Research Funding - Aston Sci (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); EirGenix (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Stemline Therapeutics (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Pfizer; Roche
 
Carlos Barrios
Stock and Other Ownership Interests - CPO; MedSIR; Thummi
Honoraria - Adium Pharma; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Aveo (Inst); BioNTech SE (Inst); BMS Brazil (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Dizal Pharma (Inst); Exelixis (Inst); Exelixis (Inst); FORTREA (Inst); FORTREA (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); ICON Clinical Research (Inst); IQvia (Inst); Janssen (Inst); LabCorp (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Novocure (Inst); Nuvisan (Inst); OBI Pharma (Inst); Parexel (Inst); Pfizer (Inst); PharmaMar (Inst); PPD Global (Inst); PSI (Inst); Regeneron (Inst); Roche/Genentech (Inst); Samsung (Inst); Sandoz (Inst); Sanofi (Inst); Servier (Inst); Sremline (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TRIO US (Inst); Worldwide Clinical Trials (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS Brazil; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech
 
Jame Abraham
Research Funding - Daiichi Sankyo/Astra Zeneca (Inst); Pfizer (Inst)
 
Aleix Prat
Employment - Reveal Genomics
Leadership - Reveal Genomics
Stock and Other Ownership Interests - Ona Therapeutics; Reveal Genomics
Honoraria - AstraZeneca; Daiichi Sankyo; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Novartis; Ona Therapeutics; Peptomyc; Roche
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Novartis (Inst); Ona Therapeutics (Inst); Reveal Genomics (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE (US 63/023785); PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; TNBC-DX
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Naoki Niikura
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly Japan; MSD; Novartis; Pfizer
Research Funding - Chugai Pharma; Daiichi Sankyo; Eisai; Mochida Pharmaceutical Co. Ltd. (Inst); Novartis (Inst); Pfizer
 
Sibylle Loibl
Employment - GBG Forschungs; Goethe Universität / Universitätsklinikum Frankurt/Main
Consulting or Advisory Role - Abbvie (Inst); American Institute of Continuing Medical Education (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BMS (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Corcept Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); Jazz Pharmaceuticals (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Lilly (Inst); Menarini Group (Inst); MICE ideas (Inst); MSD Oncology (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Speakers' Bureau - Agendia (Inst); AstraZeneca (Inst); Bayer (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); Medscape (Inst); Menarini Group (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Stemline Therapeutics (Inst); Streamedup! (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Greenwich LifeSciences (Inst); Menarini Group (Inst); MolecularHealth (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Digital Ki67 Evaluator, VM Scope GmbH (Inst); Patent Issued EP15702464.7 (Inst); Patent Pending EP14153692.0 (Inst); Patent Pending EP19808852.8 (Inst); Patent Pending EP21152186.9 (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); Gilead Sciences (Inst); MSD (Inst); Roche (Inst)
 
Charles Geyer
Honoraria - Merck; Tersera
Research Funding - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Genentech/Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi-Sankyo; Genentech/Roche; Merck
 
Cuizhi Geng
No Relationships to Disclose
 
Francisco Javier Ramírez Godinez
Research Funding - Daiichi Sankyo/Astra Zeneca (Inst)
Travel, Accommodations, Expenses - Merck
 
Chuangui Song
No Relationships to Disclose
 
Yuan Ching Chang
No Relationships to Disclose
 
Augusto Antoniazzi
No Relationships to Disclose
 
Shin-Cheh Chen
No Relationships to Disclose
 
Elton Mathias
Employment - Daiichi Sankyo/Astra Zeneca
 
Jennifer Petschauer
Employment - Daiichi Sankyo/Astra Zeneca
 
Erin Goodman
Employment - Daiichi Sankyo/Astra Zeneca; Intermountain Health/SCL Health (I)
Stock and Other Ownership Interests - Daiichi Sankyo/Astra Zeneca
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Intermountain Health/SCL Health (I)
 
Michael Jan
Employment - Daiichi Sankyo, Inc.; Organon & Co.
Stock and Other Ownership Interests - Organon & Co.
 
Yeon Hee Park
Honoraria - AimedBio; AstraZeneca; BeOne; BMS; Daiichi-Sankyo; Eisai; Gilead Sciences; Helsinn Healthcare; Lilly; MSD; Novartis; Pfizer; Roche; Voronoi Health Analytics
Consulting or Advisory Role - AimedBio; AstraZeneca; BMS; Boryung; Daiichi-Sankyo; Eisai; Gilead Sciences; Helsinn Therapeutics; Jazz Pharmaceuticals; Lilly; Menarini; MSD; Novartis; Pfizer; Roche; Voronoi Health Analytics
Research Funding - AstraZeneca; Boryung; Daewoong Pharmaceutical; Gencurix; Gencurix (Inst); Gilead Sciences; Inocras; Inocras (Inst); Kirin Pharmaceuticals; NGeneBio (Inst); Pfizer; Roche (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Gilad; Helsinn Therapeutics; Jazz Pharmaceuticals; Novartis; Pfizer; Roche